Esophagectomy - Esophagus Removal Surgery
Most esophageal cancers now meet chemotherapy before the scalpel, and in one trial the choice of regimen raised three-year survival free of recurrence from 39 to 55 percent. This page explains who is a candidate, which treatment comes first, when surgery can wait after a complete response, how minimally invasive and robotic esophagectomy compare, how the join is protected and how two to three weeks in Istanbul are planned.
About This Department
Esophagectomy removes the cancer-bearing part of the esophagus and rebuilds the swallowing tube from the stomach. Treatment before surgery comes first for deeper tumors, and keyhole surgery halves lung complications.
Esophagectomy is the main curative operation for cancer of the esophagus and the junction with the stomach. This page explains what the operation involves, who is a candidate, which treatment comes first, when surgery can wait after a complete response, how open, minimally invasive and robotic surgery compare, how the join is protected and what to send for a free review.
What esophagectomy involves
The surgeon removes the diseased esophagus and turns the stomach into a new swallowing tube.
Who is a candidate
Surgery suits cancers that have not spread beyond the esophagus and nearby lymph nodes, in patients fit enough for an operation in the chest and abdomen. Age alone rules no one out.
- Adenocarcinoma of the lower esophagus or the junction with the stomach
- Squamous cell carcinoma after chemoradiotherapy, when the tumor remains or returns
- High-grade dysplasia or early cancer that endoscopic treatment cannot clear
- Selected benign conditions, such as a stricture that no dilation can open
The treatment path
Every step runs through the tumor board.
When surgery can wait
Some tumors disappear completely after chemoradiotherapy.
In the Dutch SANO trial, 309 patients with no tumor left on biopsies, endoscopic ultrasound and PET-CT after chemoradiotherapy received either regular checks with surgery only if cancer returned, or standard surgery. Five-year survival reached 50 percent with surveillance and 54 percent with surgery, a difference that did not reach statistical significance, and 43 percent of the surveillance group never needed an esophagectomy. Distant spread ran higher under surveillance, 46 against 29 percent. Swallowing, breathing and energy were better at six months for patients under surveillance, and swallowing stayed better at two years. Squamous cell cancer and adenocarcinoma gave similar results. Choice matters. Surveillance suits patients who accept frequent checks and understand that an operation, if needed, comes later and sometimes after the cancer has spread, so the tumor board reviews each response with you before you decide, and the decision can change at any visit with your surgeon and oncologist both present.
Chemotherapy or chemoradiotherapy first
The German ESOPEC trial randomized 438 patients with esophageal adenocarcinoma to FLOT chemotherapy before and after surgery or to the CROSS regimen of chemoradiotherapy before it. Among the 371 who reached surgery, three-year survival free of recurrence was 54.5 percent after FLOT and 39.0 percent after CROSS, a hazard ratio of 0.67. Fifteen points. The gain came from fewer distant recurrences, 31.5 against 47.2 percent, while recurrence near the original tumor stayed the same. Squamous cell cancer, the type common in Asia and the Middle East, still receives chemoradiotherapy.
This table scrolls sideways on a narrow screen. Swipe or drag to see every column.
| Measure | FLOT | CROSS |
|---|---|---|
| Patients randomized | 221 | 217 |
| Reached surgery | 86.9% | 82.5% |
| Three-year survival free of recurrence | 54.5% | 39.0% |
| Distant recurrence at three years | 31.5% | 47.2% |
| Local recurrence at three years | 20.2% | 17.4% |
Tests before surgery
- Endoscopy with biopsy and endoscopic ultrasound
- CT of the chest and abdomen, and a PET-CT
- Breathing tests and an echocardiogram
- A nutrition assessment, with a feeding plan if you have lost weight
- Blood tests and a review of your medications
Open, minimally invasive or robotic
Across eight randomized trials with 1,776 patients, minimally invasive and robotic esophagectomy cut lung complications by more than half against open surgery, relative risks of 0.46 and 0.48, with shorter hospital stays and the same leak rate, deaths in hospital and cancer clearance. Lungs benefit most. A review of 16 randomized trials with 2,729 patients found higher death rates within 30 days after open surgery, a relative risk of 1.84, and better physical function a year later after minimally invasive operations. Three randomized trials with 549 patients found robotic and conventional approaches level on leaks, pneumonia and complete resection.
On a phone, slide this table sideways to read all of its columns.
| Measure | Finding |
|---|---|
| Lung complications | Less than half the risk, relative risks 0.46 and 0.48 |
| Hospital stay | Shorter |
| Anastomotic leak | No difference |
| Deaths within 30 days | Higher after open surgery, relative risk 1.84 |
| Survival | Comparable |
The join and the first weeks
A leak from the join between the stomach tube and the esophagus ranks among the most serious complications. Prevention starts in the operating room. Across nine studies with 2,227 patients, wrapping the join in a flap of omentum, the fatty apron of the abdomen, cut leaks by two thirds, a risk ratio of 0.32, and one leak was prevented for every 13 patients wrapped.
- One or two nights in intensive care
- Feeding through the bowel tube from the first day
- A check of the join before you drink
- Liquids, then soft food, then small solid meals
- Discharge once you eat enough and walk the corridor
Treatment after surgery
When cancer cells remain in the specimen after chemoradiotherapy and surgery, a year of nivolumab immunotherapy follows. The CheckMate 577 trial showed longer survival free of disease. A Dutch national registry later compared 311 matched pairs of patients with and without nivolumab and found two-year survival of 66.8 against 58.8 percent, a hazard ratio of 0.75. A real-world gain. After FLOT, the remaining four cycles of chemotherapy come once you recover from surgery.
Drag sideways on a narrow screen to see the whole table.
| Measure | Nivolumab | No nivolumab |
|---|---|---|
| Matched patients | 311 | 311 |
| Two-year survival | 66.8% | 58.8% |
| Hazard ratio for death | 0.75 | Reference |
Your time in Istanbul
One published Istanbul package for esophageal resection, at Memorial Şişli, lists seven days in hospital. Airfare and hotel sit outside it. After esophagectomy for cancer, we plan two to three weeks in the city, longer when a complication slows recovery. Patience pays.
A single coordinator handles your trip on WhatsApp, from the first message to the last follow-up call once you are back home. The team speaks English, Arabic, French, Russian, Serbian, Romanian and Spanish, and an interpreter covers other languages. A relative may sleep in your room on the companion bed. The international patients office books a hotel close to the hospital, collects you at the airport and drives you to every appointment, a female surgeon operates on request where the rota allows, and the kitchen serves halal, vegetarian and diabetic meals, with a prayer room in the building. Your visa invitation letter leaves ten days before you travel. Swallowing stays slow in the first weeks, so we pack soft snacks and liquid feeds for the journey, arrange wheelchair help at both airports and ask you to walk the aisle every hour against clots. Back home, your oncologist and dietitian receive the reports in English, and the surgeon checks your weight and swallowing by video call.
Call us the same day for fever, chest or neck pain, a new cough after drinking, vomiting, difficulty swallowing that gets worse, or calf pain. Any hour.
What the cost depends on
Cost depends on open, minimally invasive or robotic surgery, an Ivor Lewis or McKeown operation, any chemotherapy or chemoradiotherapy given in Istanbul, the nights in intensive care and on the ward, and the feeding tube and nutrition support afterwards. The written quote arrives after the review. It names every item it covers, so treatment given at home before or after surgery stays outside it.
Scroll the table left and right on a small screen to see each column.
| Factor | Effect |
|---|---|
| Robotic surgery | Higher operating room cost |
| Minimally invasive surgery | Shorter stay |
| Chemotherapy in Istanbul | Adds cycles and weeks |
| Complications | Extra nights and procedures |
| Feeding support | Formula and dietitian visits |
Esophagectomy FAQ
Your endoscopy report, biopsy and scans shape the plan before you travel.
Can I eat normally without an esophagus?
Do I need chemotherapy before surgery?
Can I avoid surgery?
Will my voice change?
What should I send for a free review?
Scan images on a download link or disc let the surgeon plan before you travel.
References
- Panday SSGG, van der Wilk BJ, Lagarde SM, et al. Active surveillance versus standard surgery after neoadjuvant chemoradiotherapy for oesophageal cancer: long-term results of a cluster-randomised controlled trial (SANO). Ann Oncol. 2026. doi:10.1016/j.annonc.2026.10.1290.
- Gangaram Panday SSG, van der Wilk BJ, Eyck BM, et al. Health-related quality of life of patients undergoing active surveillance versus standard surgery for oesophageal cancer (SANO trial). Br J Surg. 2026;113(1). doi:10.1093/bjs/znaf286.
- Hoeppner J, Schmoor C, Brunner T, et al. Recurrence patterns of esophageal adenocarcinoma in the phase III ESOPEC trial comparing perioperative chemotherapy with preoperative chemoradiotherapy. J Clin Oncol. 2025;43(32):3451-3456.
- Aiolfi A, Cammarata F, Bonitta G, Bona D, Bonavina L. Open, hybrid, minimally invasive, and robotic-assisted transthoracic esophagectomy for cancer: a network meta-analysis of randomized trials. Int J Surg. 2025;111(11):8503-8514.
- Dunne N, Davey MG, Donlon NE. Comparing outcomes following open, hybrid, minimally invasive, and robotic-assisted esophagectomy: a systematic review. Eur J Surg Oncol. 2026;52(1):110531.
- Mirza W, Khan ME, Iqbal H, et al. Robot-assisted (da Vinci) versus conventional esophagectomy for resectable esophageal cancer: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials. J Robot Surg. 2025;19(1):742.
- Fouad M, Sourial K, Ibraheim S. Impact of omental flap reinforcement on anastomotic leak after esophagectomy: updated evidence incorporating minimally invasive and high-volume contemporary series. Dis Esophagus. 2026;39(3). doi:10.1093/dote/doag061.
- Verhoeven RHA, Kuijper SC, Slingerland M, et al. Adjuvant nivolumab after chemoradiotherapy and resection for patients with esophageal cancer: a real-world matched comparison of overall survival. Int J Cancer. 2026;158(5):1292-1301.
Editor's note
Written by the Biruni Hospital medical editorial team. Reviewed by Prof. Dr. Mustafa Teoman YANMAZ, Medical Oncology.
Medically reviewed by
Prof. Dr. Mustafa Teoman YANMAZ
Medical Oncology
Last updated: